The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
Open accessAbstract
OBJECTIVE: To determine the efficacy and tolerability of topical pimecrolimus and tacrolimus compared with other treatments for atopic dermatitis. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic searches of the Cochrane Library, Medline, and Embase. STUDY SELECTION: Randomised controlled trials of topical pimecrolimus or tacrolimus reporting efficacy outcomes or tolerability. EFFICACY: investigators' global assessment of response; patients' global assessment of response; proportions of patients with flares of atopic dermatitis; and improvements in quality of life. Tolerability: overall rates of withdrawal; withdrawal due to adverse events; and proportions of patients with burning of the skin and skin infections. DATA SYNTHESIS: 4186 of 6897 participants in 25 randomised controlled trials received pimecrolimus or tacrolimus. Both drugs were significantly more effective than a vehicle control. Tacrolimus 0.1% was as effective as potent topical corticosteroids at three weeks and more effective than combined treatment with hydrocortisone butyrate 0.1% (potent used on trunk) plus hydrocortisone acetate 1% (weak used on face) at 12 weeks (number needed to treat (NNT) = 6). Tacrolimus 0.1% was also more effective than hydrocortisone acetate 1% (NNT = 4). In comparison, tacrolimus 0.03% was more effective than hydrocortisone acetate 1% (NNT = 5) but less effective than hydrocortisone butyrate 0.1% (NNT = -8). Direct comparisons of tacrolimus 0.03% and tacrolimus 0.1% consistently favoured the higher strength formulation, but efficacy differed significantly between the two strengths only after 12 weeks' treatment (rate ratio 0.80, 95% confidence interval 0.65 to 0.99). Pimecrolimus was far less effective than betamethasone valerate 0.1% (NNT = -3 at three weeks). Pimecrolimus and tacrolimus caused significantly more skin burning than topical corticosteroids. Rates of skin infections in any of the comparisons did not differ. CONCLUSIONS: Both topical pimecrolimus and topical tacrolimus are more effective than placebo treatments for atopic dermatitis, but in the absence of studies that show long term safety gains, any advantage over topical corticosteroids is unclear. Topical tacrolimus is similar to potent topical corticosteroids and may have a place for long term use in patients with resistant atopic dermatitis on sites where side effects from topical corticosteroids might develop quickly. In the absence of key comparisons with mild corticosteroids, the clinical need for topical pimecrolimus is unclear. The usefulness of either treatment in patients who have failed to respond adequately to topical corticosteroids is also unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Williams, H., Robertson, C., Stewart, A., Aït-Khaled, N., Anabwani, G., Anderson, R., Asher, I., Beasley, R., Björkstén, B., Burr, M., et al. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70536-1 · Cited by 998
Self-citationTopical corticosteroid phobia in patients with atopic eczema: CORTICOSTEROID PHOBIA IN ATOPIC ECZEMA
Charman, C. R., Morris, A. D., & Williams, H. C. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03473.x · Cited by 590
Self-citationA Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis
Ruzicka, T., Bieber, T., Schöpf, E., Rubins, A., Dobozy, A., Bos, J. D., Jablonska, S., Ahmed, I., Thestrup-Pedersen, K., Daniel, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371203 · Cited by 518
Wahn, U., Bos, J. D., Goodfield, M., Caputo, R., Papp, K., Manjra, A., Dobozy, A., Paul, C., Molloy, S., Hultsch, T., et al. (2002) · Pediatrics · doi:10.1542/peds.110.1.e2 · Cited by 404
The Infants’ Dermatitis Quality of Life Index
Lewis-Jones, M. S., Finlay, A. Y., & Dykes, P. J. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.03960.x · Cited by 384
Eichenfield, L. F., Lucky, A. W., Boguniewiczc, M., Langley, R. G. B., Cherille, R., Marshalle, K., Bushe, C., & Graeber, M. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.122187 · Cited by 366
A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
Paller, A., Eichenfield, L. F., Leung, D. Y. M., Stewart, D., & Appell, M. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109813 · Cited by 324
Boguniewicz, M., Fiedler, V. C., Raimer, S., Lawrence, I. D., Leung, D. Y. M., & Hanifin, J. M. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70281-7 · Cited by 309
Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
Hanifin, J. M., Ling, M. R., Langley, R., Breneman, D., & Rafal, E. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109810 · Cited by 286
Atopic dermatitis is associated with a decrement in health‐related quality of life
Kiebert, G., Sorensen, S. V., Revicki, D., Fagan, S. C., Doyle, J. J., Cohen, J., & Fivenson, D. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01436.x · Cited by 286
Kapp, A., Papp, K., Bingham, A., Fölster-Holst, R., Ortonne, J.-P., Potter, P. C., Gulliver, W., Paul, C., Molloy, S., Barbier, N., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.126500 · Cited by 272
Reitamo, S., Rustin, M., Ruzicka, T., Cambazard, F., Kalimo, K., Friedmann, P. S., Schoepf, E., Lahfa, M., Diepgen, T. L., Judodihardjo, H., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121832 · Cited by 258
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis
Luger, T., Van Leent, E. J. M., Graeber, M., Hedgecock, S., Thurston, M., Kandra, A., Berth-Jones, J., Bjerke, J., Christophers, E., Knop, J., et al. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04134.x · Cited by 241
Reitamo, S., Van Leent, E. J. M., Ho, V., Harper, J., Ruzicka, T., Kalimo, K., Cambazard, F., Rustin, M., Taïeb, A., Gratton, D., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121831 · Cited by 237
Queille-Roussel, C., Paul, C., Duteil, L., Lefebvre, M.-C., Rapatz, G., Zagula, M., & Ortonne, J.-P. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04076.x · Cited by 219
Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study
Meurer, M., Fölster-Holst, R., Wozel, G., Weidinger, G., Jünger, M., Bräutigam, M., & for the CASM-DE-01 Study Group, F. (2002) · Dermatology · doi:10.1159/000065863 · Cited by 218
Outcome Measures of Disease Severity in Atopic Eczema
Charman, C., & Williams, H. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.6.763 · Cited by 203
Self-citationHo, V. C., Gupta, A., Kaufmann, R., Todd, G., Vanaclocha, F., Takaoka, R., Fölster-Holst, R., Potter, P., Marshall, K., Thurston, M., et al. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.65 · Cited by 200
Fonseca, B. K., Holdgate, A., & Craig, J. C. (2004) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.158.5.483 · Cited by 179
Charman, C., Chambers, C., & Williams, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12251.x · Cited by 160
Self-citationDrake, L. A., Prendergast, M. M., Maher, R., Breneman, D., Korman, N. J., Satoib, Y., Beusterien, K. M., & Lawrence, I. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.109814 · Cited by 144
Reitamo, S., Harper, J. I., Bos, J. D., Cambazard, F., Bruijnzeel-Koomen, C. A. F. M., van der Valk, P. G. M., Smith, C. H., Moss, C., DOBOZY, A., Palatsi, R., et al. (2004) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2004.05782.x · Cited by 128
What is the cost of atopic dermatitis in preschool children?
Emerson, R. M., Williams, H. C., & Allen, B. R. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04077.x · Cited by 119
Self-citationLuger, T., Lahfa, M., Fölster‐Holst, R., Gulliver, W., Allen, R., Molloy, S., Barbier, N., Paul, C. F., & Bos, J. D. (2004) · Journal of Dermatological Treatment · doi:10.1080/09546630410033781 · Cited by 119
Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis
Beattie, P. E., & Lewis‐Jones, M. S. (2003) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2003.01357.x · Cited by 103
Kyllönen, H., Remitz, A., Mandelin, J. M., Elg, P., & Reitamo, S. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06017.x · Cited by 93
Whalley, D., Huels, J., McKenna, S. P., & van Assche, D. (2002) · PEDIATRICS · doi:10.1542/peds.110.6.1133 · Cited by 92
Bellemare, S., Hartling, L., Wiebe, N., Russell, K. F., Craig, W. R., McConnell, D., & Klassen, T. P. (2004) · BMC Medicine · doi:10.1186/1741-7015-2-11 · Cited by 88
Pacor, M. L., Lorenzo, G. D., Martinelli, N., Mansueto, P., Rini, G. B., & Corrocher, R. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.1907.x · Cited by 70
The morbidity and cost of atopic dermatitis
Herd, R. M. (2000) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545771.008 · Cited by 26
Effects of UVB on the Synthesis of Complement Proteins by Keratinocytes
Pasch, M. C., Okada, N., Bos, J. D., & Asghar, S. S. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00358.x · Cited by 11
Cited by
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Chamlin, S. L., Feldman, S. R., Hanifin, J. M., Simpson, E. L., Berger, T. G., Bergman, J. N., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.10.010 · Cited by 1,277
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationAkdis, C. A., Akdis, M., Bieber, T., Bindslev‐Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01153.x · Cited by 733
Metadata
- Authors
- Ashcroft, D. M., Dimmock, P., Garside, R., Stein, K., & Williams, H. C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2005-02-24
- Volume
- 330
- Issue
- 7490
- Pages
- 516
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2044053588
- Cited by
- 294
- References
- 38
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.